EUCTR2005-000793-45-IT进行中（未招募）不适用
Open-label safety study of TMC114 in combination with low dose RTV and other ARVs in highly experienced HIV-1 infected patients with limited or no treatment options
TIBOTEC PHARMACEUTICALS LTD.0 个研究点目标入组 600 人开始时间: 2007年2月9日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Open-label safety study of TMC114 in combination with low dose RTV and other ARVs in highly experienced HIV-1 infected patients with limited or no treatment options.HIV-1 infected patientMedDRA version: 7.1Level: 4Classification code 10020161EUCTR2005-000793-45-DETibotec Pharmaceuticals Ltd.600
已完成
3 期
TMC114-C209: A Study of Safety of TMC114 With Low Dose Ritonavir (RTV) and Other Antiretrovirals in Experienced HIV-1 Infected Patients With Limited or no Treatment OptionsHIV InfectionsNCT00115050Tibotec Pharmaceuticals, Ireland260
已完成
3 期
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced PatientsHIV InfectionNCT00110877Tibotec Pharmaceuticals, Ireland604
已完成
3 期
TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir ("TMC114/r") in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.HIVNCT00258557Tibotec Pharmaceuticals, Ireland692
已完成
2 期
A Phase II Open-Label Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of ATL1103 300mg in Adult Patients with Acromegaly.AcromegalyACTRN12615000289516Antisense Therapeutics Limited3